|Bid||22.27 x 800|
|Ask||23.40 x 1000|
|Day's range||22.25 - 23.49|
|52-week range||13.63 - 36.85|
|Beta (5Y monthly)||1.99|
|PE ratio (TTM)||N/A|
|Earnings date||06 Aug 2020 - 10 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||31.21|
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Nektar Therapeutics...
Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22.02.
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, setting a price target of $26, which is approximately 25.18% above the present share price of $20.77.
Nektar (NKTR) delivered earnings and revenue surprises of 34.57% and 12.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Celebrations may be in order for Nektar Therapeutics (NASDAQ:NKTR) shareholders, with the analysts delivering a...
It's been a sad week for Nektar Therapeutics (NASDAQ:NKTR), who've watched their investment drop 12% to US$20.81 in...
Howard Robin became the CEO of Nektar Therapeutics (NASDAQ:NKTR) in 2007. This analysis aims first to contrast CEO...
We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether Nektar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.
Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.
Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
Nektar (NKTR) delivered earnings and revenue surprises of 23.29% and 11.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.